The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis von Mills, Edward J, Kanters, Steve, Hagopian, Amy, Bansback, Nick, Nachega, Jean, Alberton, Mark, Au-Yeung, Christopher G, Mtambo, Andy, Bourgeault, Ivy L, Luboga, Samuel, Hogg, Robert S, Ford, Nathan

Volltext

The changing role for extended resections in an era of advanced radiotherapy techniques and novel therapies in gynaecological malignancy von McBain, R.D., McGauran, M.F.G., Tran, K.H., Au-Yeung, G., Khaw, P.Y.L., McNally, O.M.

Volltext

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclita... von Sivakumaran, T., Mileshkin, L., Grant, P., Na, L., DeFazio, A., Friedlander, M., Obermair, A., Webb, P.M., Au-Yeung, G.

Volltext

Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program von Au-Yeung, Christopher G, Anema, Aranka, Chan, Keith, Yip, Benita, Montaner, Julio S G, Hogg, Robert S

Volltext

Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020 von Anema, Aranka, Au-Yeung, Christopher G, Joffres, Michel, Kaida, Angela, Vasarhelyi, Krisztina, Kanters, Steve, Montaner, Julio Sg, Hogg, Robert S

Volltext

HAART slows progression to anal cancer in HIV-infected MSM von Duncan, Katrina C, Chan, Keith J, Chiu, Connie G, Montaner, Julio S G, Coldman, Andy J, Cescon, Angela, Au-Yeung, Christopher G, Wiseman, Sam M, Hogg, Robert S, Press, Natasha M

Volltext

572P Estimating rates of immune-related adverse events in an Australian state-wide hospital population von Jayathilaka, B., He, F., Ijzerman, M., Au-Yeung, G., Franchini, F.

Volltext

819TiP FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours von Meric-Bernstam, F., Song, M., Westin, S.N., Au-Yeung, G., Mitchell, P., Myers, C., Gymnopoulos, M., Fraenkel, P.G., Nawinne, M., Brier, T., Mileshkin, L.

Volltext

72MO Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effecti... von Braden, J., Conway, J.W., Ramanathan, A., Smith, L.A., Menzies, A.M., Carlino, M.S., Au-Yeung, G., Rawson, R., Shannon, K.F., Pennington, T.E., Ch'ng, S., Saw, R.P.M., Spillane, A.J., Gyokri, D., Howle, J., Wilmott, J., Scolyer, R.A., Long, G.V., Pires da Silva, I.

Volltext

752P Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival von Zwimpfer, T.A., Pandey, A., Fereday, S., Coelho, R.J.B-N., Twomey, L., Ariyaratne, D., Traficante, N., Jacob, F., Eller, R., Heinzelmann-Schwarz, V., Christie, E.L., Kennedy, C., Au-Yeung, G., Ramus, S., Koebel, M., Nelson, B., Goode, E.L., DeFazio, A., Bowtell, D.D.L., Garsed, D.W.

Volltext

452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escal... von Voskoboynik, M., Mileshkin, L., Gan, H., Millward, M., Au-Yeung, G., Meniawy, T.M., Kichenadasse, G., Zhang, K., Zhang, M., Mu, S., Lickliter, J.D.

Volltext

452PDSafety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalati... von Voskoboynik, M, Mileshkin, L, Gan, H, Millward, M, Au-Yeung, G, Meniawy, T M, Kichenadasse, G, Zhang, K, Zhang, M, Mu, S, Lickliter, J D

Volltext

Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/ex... von Voskoboynik, M., Mileshkin, L., Gan, H., Millward, M., Au-Yeung, G., Meniawy, T.M., Kichenadasse, G., Zhang, K., Zhang, M., Mu, S., Lickliter, J.D.

Volltext

798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis von Braden, J., Potter, A.J., Paver, E.C., Rawson, R., Menzies, A.M., Carlino, M.S., Au-Yeung, G., Saw, R.P.M., Spillane, A.J., Shannon, K.F., Pennington, T.E., Ch'ng, S., Gyorki, D., Howle, J., Daneshvar, D., Wilmott, J.S., Lo, S.N., Pires da Silva, I., Scolyer, R.A., Long, G.V.

Volltext

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer von Burdett, Nikki L., Willis, Madelynne O., Pandey, Ahwan, Twomey, Laura, Alaei, Sara, Bowtell, David D. L., Christie, Elizabeth L.

Volltext

Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci von DeVries, Amber A, Dennis, Joe, Tyrer, Jonathan P, Peng, Pei-Chen, Coetzee, Simon G, Reyes, Alberto L, Plummer, Jasmine T, Davis, Brian D, Chen, Stephanie S, Dezem, Felipe Segato, Aben, Katja K H, Anton-Culver, Hoda, Antonenkova, Natalia N, Beckmann, Matthias W, Beeghly-Fadiel, Alicia, Berchuck, Andrew, Bogdanova, Natalia V, Bogdanova-Markov, Nadja, Brenton, James D, Butzow, Ralf, Campbell, Ian, Chang-Claude, Jenny, Chenevix-Trench, Georgia, Cook, Linda S, DeFazio, Anna, Doherty, Jennifer A, Dörk, Thilo, Eccles, Diana M, Eliassen, A Heather, Fasching, Peter A, Fortner, Renée T, Giles, Graham G, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Håkansson, Niclas, Hildebrandt, Michelle A T, Huff, Chad, Huntsman, David G, Jensen, Allan, Kar, Siddhartha, Karlan, Beth Y, Khusnutdinova, Elza K, Kiemeney, Lambertus A, Kjaer, Susanne K, Kupryjanczyk, Jolanta, Labrie, Marilyne, Lambrechts, Diether, Le, Nhu D, Lubiński, Jan, May, Taymaa, Menon, Usha, Milne, Roger L, Modugno, Francesmary, Monteiro, Alvaro N, Moysich, Kirsten B, Odunsi, Kunle, Olsson, Håkan, Pearce, Celeste L, Pejovic, Tanja, Ramus, Susan J, Riboli, Elio, Riggan, Marjorie J, Romieu, Isabelle, Sandler, Dale P, Schildkraut, Joellen M, Setiawan, V Wendy, Sieh, Weiva, Song, Honglin, Sutphen, Rebecca, Terry, Kathryn L, Thompson, Pamela J, Titus, Linda, Tworoger, Shelley S, Van Nieuwenhuysen, Els, Edwards, Digna Velez, Webb, Penelope M, Wentzensen, Nicolas, Whittemore, Alice S, Wolk, Alicja, Wu, Anna H, Ziogas, Argyrios, Freedman, Matthew L, Lawrenson, Kate, Pharoah, Paul D P, Easton, Douglas F, Gayther, Simon A, Jones, Michelle R

Volltext

P072 Developing Generative AI Products for Sleep Health Support: A Risk-Based Approach von Deas, R, Cotton, A, Santizo, R, Webb, K, Signoroni, M, Tjia, J, Li, M, Au-Yeung, G, Lyle, A, Silva, C, Armitstead, J

Volltext

737P Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP) von Ngoi, N.Y.L., Tan, T.Z., Kuay, K.T., Tan, A.C.Y., Lee, J.Y., Pang, M.Y., Tham, K.W., Chan, J., Wong, W.L., Chay, W.Y., Anne, D., Friedlander, M., Varma, S., Meniawy, T., Au-Yeung, G., Scott, C., Mileshkin, L., Bowtell, D., Huang, R.Y-J., Tan, D.S.P.

Volltext

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer von Burdett, Nikki L., Willis, Madelynne O., Pandey, Ahwan, Fereday, Sian, DeFazio, Anna, Bowtell, David D. L., Christie, Elizabeth L.

Volltext

Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC) von Weppler, A.M., Bhave, P., De Ieso, P., Chua, M., Raleigh, J., Hatzimihalis, A., Gill, A., Balachander, S., Callahan, J., Pattison, A., Caneborg, A., Au Yeung, G., McArthur, G., Hicks, R.J., Tothill, R., Sandhu, S.K.

Volltext